Invasive mould infections in the ICU setting: complexities and solutions

Area of Science:

• Critical care medicine
• Infectious diseases
• Mycology

Background:

• Filamentous fungal infections, including invasive aspergillosis and mucormycosis, pose a substantial challenge in intensive care units (ICUs).
• Invasive aspergillosis is increasingly seen in non-neutropenic patients with risk factors such as corticosteroid use, COPD, liver cirrhosis, cancer, HIV, and transplantation.
• Mucormycosis, though rare, is prevalent in uncontrolled diabetes, immunocompromised states, and post-traumatic contamination, often requiring ICU care.

Purpose of the Study:

• To review the current understanding of invasive aspergillosis and mucormycosis in the ICU setting.
• To highlight diagnostic challenges and therapeutic strategies for these severe fungal infections.
• To emphasize the importance of early intervention and management in critically ill patients.

Main Methods:

• Review of current literature on filamentous fungal infections in ICUs.
• Analysis of diagnostic criteria and interpretation of laboratory tests for invasive aspergillosis.
• Evaluation of therapeutic options, including antifungal agents and surgical interventions for mucormycosis.

Main Results:

• Diagnosis of invasive aspergillosis is difficult due to non-specific symptoms and low clinical suspicion, necessitating cautious interpretation of diagnostic tests.
• Antifungal therapy for invasive aspergillosis should be initiated promptly based on suspicion, with voriconazole and isavuconazole as preferred agents.
• Mucormycosis diagnosis relies on identifying non-septate hyphae in tissues, with treatment focusing on underlying conditions, surgery, and liposomal amphotericin B, though mortality remains high.

Conclusions:

• Prompt initiation of antifungal therapy for invasive aspergillosis in ICU patients is critical, even without definitive proof.
• Management of mucormycosis requires a multi-faceted approach including surgical debridement and effective antifungal treatment, with isavuconazole as a potential alternative.
• Despite advances, both invasive aspergillosis and mucormycosis carry high mortality rates in the ICU, underscoring the need for improved diagnostics and therapeutics.